ArticleJournal of biomolecular techniques : JBT2018
Challenges and Opportunities for Biological Mass Spectrometry Core Facilities in the Developing World.
Article in Journal of biomolecular techniques : JBT, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Evaluating First-Pass, High Protein Capacity Desalting Techniques For Phosphoproteomics Applications.bioRxiv : the preprint server for biology · 2025Article
- Core Facility for Supporting Research and Technological Development in Health: A Review of Its Concept and the Brazilian Context.TheScientificWorldJournal · 2025Review
- Review of the Use of Liquid Chromatography-Tandem Mass Spectrometry in Clinical Laboratories: Part II-Operations.Annals of laboratory medicine · 2022Review
- Liquid chromatography-tandem mass spectrometry for clinical diagnostics.Nature reviews. Methods primers · 2022Review
- Clinical Chemistry for Developing Countries: Mass Spectrometry.Annual review of analytical chemistry (Palo Alto, Calif.) · 2021Review
- Nontargeted mass spectrometry of dried blood spots for interrogation of the human circulating metabolome.Journal of mass spectrometry : JMS · 2021Article
- Gold-silver core-shell nanoparticle-based impedimetric immunosensor for detection of iron homeostasis biomarker hepcidin.Mikrochimica acta · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The developing world is seeing rapid growth in the availability of biological mass spectrometry (MS), particularly through core facilities. As proteomics and metabolomics becomes locally feasible for investigators in these nations, application areas associated with high burden in these nations, such as infectious disease, will see greatly increased research output. This article evaluates the rapid growth of MS in South Africa (currently approaching 20 laboratories) as a model for establishing MS core facilities in other nations of the developing world. Facilities should emphasize new services rather than new instruments. The reduction of the delays associated with reagent and other supply acquisition would benefit both facilities and the users who make use of their services. Instrument maintenance and repair, often mediated by an in-country business for an international vendor, is also likely to operate on a slower schedule than in the wealthiest nations. A key challenge to facilities in the developing world is educating potential facility users in how best to design experiments for proteomics and metabolomics, what reagents are most likely to introduce problematic artifacts, and how to interpret results from the facility. Here, we summarize the experience of 6 different institutions to raise the level of biological MS available to researchers in South Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.